EXOC4

Across TCGA pan-cancer cohorts, EXOC4 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated EXOC4 data layer compared with 27 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher EXOC4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EXOC4 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

UCS, UCEC, and BLCA are the cancer types where EXOC4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Median	All	0.102	0.688	<.001	36	view →
UCEC	DFS	Median	II,III,IV	0.933	0.435	.016	18	view →
BLCA	DFS	Median	All	0.726	0.322	.026	12	view →
LIHC	OS	Median	All	0.098	0.774	.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

EXOC4–UCS (OS)

Open the UCS breakdown →